Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean 744 24 8?
Displaying drugs 626 - 650 of 2022 in total
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
Approved
Investigational
Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of...
Approved
Matched Description: … On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 …
Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, spermidine and spermine. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. Initially approved by the FDA in 1985...
Approved
Investigational
Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved...
Approved
Investigational
Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954.
Approved
Vet approved
Matched Description: … [A189522] Primidone was granted FDA Approval on 8 March 1954.[L11112] …
Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides. FDA approved on...
Approved
Investigational
Nutraceutical
Matched Description: … FDA approved on July 26, 2012. …
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities...
Approved
Matched Mixtures name: … UNISIA 8 MG/5 MG ... UNISIA 8 MG/5 MG ... CANDEAMLO HEX 8/5MG HKP …
Matched Products: … AMLESSA TABLETS 8 mg/ 5mg ... AMLESSA TABLETS 8 mg/ 10 mg …
A phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium, such as the aqueous humor, and is used therapeutically as a diagnostic aid in corneal injuries and corneal trauma. It has been approved by FDA for use in externally applied drugs...
Approved
Matched Salts cas: … 518-47-8
Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough...
Approved
Investigational
Tilactase is a beta-D-galactosidase obtained from Aspergillus oryzae. It is produced as a chewable tablet that has to be taken before the consumption of a lactose-containing meal. The beta-D-galactosidase us a large monomeric multi-domain enzyme of 985 residues that presents a catalytic (alpha/beta)8-barrel domain. It is considered by the WHO...
Approved
Experimental
Matched Description: … beta-D-galactosidase us a large monomeric multi-domain enzyme of 985 residues that presents a catalytic (alpha/beta)8- …
Birch bark extract is rich in triterpenoids with beneficial biological and pharmacological activities. Some of the compounds identified in it include betulin, lupeol, betulinic acid, oleanolic acid, and erythrodiol. Birch bark extract is obtained from the white part of the birch tree bark, and the main species of trees used...
Approved
Experimental
Approved
Nutraceutical
Matched Mixtures name: … A/o-26 - Caplet …
Commonly known as 4-methylbenzylidene-camphor (4-MBC), enzacamene is a camphor derivative and an organic chemical UV-B filter. It is used in cosmetic products such as sunscreen to provide skin protection against UV rays. While its effects on the human reproductive system as an endocrine disruptor are being investigated, its use in...
Approved
Matched Mixtures name: … Sebamed Sun Cream SPF 8 ... Sebamed Sun Lotion SPF 8 ... Soin Solaire Autobronzant SPF 8 - Crm …
Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and...
Approved
Investigational
Vet approved
Matched Products: … ETIDOKS 100 MG KAPSÜL, 8 ADET …
Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
Approved
Investigational
Albutrepenonacog alfa (rIX-RFP) is a recombinant fusion protein that links a recombinant coagulation factor IX (rFIX) with a recombinant human albumin (rAlbumin). It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016. It...
Approved
Matched Description: … [A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. …
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be...
Approved
The relief of pain (analgesia) is a primary goal for enhancing the quality of life of patients and for increasing the ability of patients to engage in day to day activities. Codeine, an opioid analgesic, was originally approved in the US in 1950 and is a drug used to decrease...
Approved
Illicit
Matched Salts cas: … 52-28-8 ... 6059-47-8
Matched Mixtures name: … Exdol-8 ... Atasol 8 ... Triatec-8
An anti-infective agent that is used topically to treat skin infections and orally for urinary tract infections.
Approved
Matched Mixtures name: … SulfaCleanse 8/4 ... Sodium Sulfacetamide 8% and Sulfur 4% ... Sodium Sulfacetamide 8% and Sulfur 4% …
Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.
Approved
Matched Iupac: … (6R,7R)-7-[(2R)-2-amino-2-phenylacetamido]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic …
Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)
Approved
Investigational
Nutraceutical
Matched Mixtures name: … HEPATAMINE %8 500 ML(SETLI) ... HEPATAMINE %8 500 ML(SETSIZ) …
Peanut allergenic extract is used in allergenic testing.
Approved
Matched Mixtures name: … PALFORZIA (Level 8) ... PALFORZIA (Level 8) …
Approved
Experimental
Matched Mixtures name: … Racord Two No 8 ... Sil Trax Plus No 8
Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.
Approved
Matched Salts cas: … 705260-08-8
Carya ovata pollen is the pollen of the Carya ovata plant. Carya ovata pollen is mainly used in allergenic testing.
Approved
Matched Mixtures name: … Eastern 8 Tree Pollen Mix ... Eastern 8 Tree Pollen Mix ... Eastern 8 Tree Pollen Mix …
Displaying drugs 626 - 650 of 2022 in total